Neuro Program
Neurodegeneration / Traumatic Brain Injury
Key Facts
About MicroQuin
MicroQuin is a private, preclinical-stage biotech developing first-in-class therapeutics that target the IntraCellular Environment (ICE) to treat cancer, viral infections, and neurodegeneration. Its core hypothesis is that disease progression is driven by destabilization of the cellular interior, and its drugs aim to restore balance by modulating specific ICE regulators. The company has garnered non-dilutive funding from government grants and established a key collaboration with Eli Lilly's TuneLab, positioning its lead oncology program for potential IND-enabling studies. MicroQuin represents a high-risk, high-reward venture targeting fundamental biological mechanisms across multiple major therapeutic areas.
View full company profile